NFKB1 and Miyoshi myopathy: The most conclusive affirmation of this key role of NF-κB in MM has come from the discovery of a diverse array of genetic alterations targeting components of the NF-κB pathway, such as the upstream activator, NF-κB-inducing kinase and the inhibitor tumor necrosis factor receptor-associated factor 3, in about 20% of MM patients and more than 40% of MM cell lines (Annunziata et al., 2007, Keats et al., 2007, Demchenko et al., 2010, Chapman et al., 2011).